Sign up
Pharma Capital

Akers Bio expects sales of its ‘morning after’ alcohol breath test to ramp up as distributor secures major new channel partner

"Today's Group is the biggest buying group of its kind in the UK and represents a significant revenue opportunity for Akers Bio”
alcohol and car keys
Accutest’s tie-up with Today’s Group opens up Akers’ product to large new set of potential customers

Akers Biosciences, Inc. (LON:AKR; NASDAQ:AKER) expects sales of its BreathScan alcohol detector to “ramp up” in the coming months after its UK distributor Accutest secured a “major new channel partner” in Today’s Wholesale Services Group.

Today’s Wholesale Services is a subsidiary of Today’s Group, the largest independent buying group of its kind in the UK with buying power exceeding £5.7bn a year.

READ: Akers Bio sees 'material commercial growth' for Heparin allergy test

Akers said the tie-up with a company with such big buying power represents “a significant revenue opportunity”.

Accutest will initially market the device under its own label to a select few of Today’s wholesale customers before the marketing program is then be rolled out to the “full and extensive” client list.

“Significant revenue opportunity”

"Today's Group is the biggest buying group of its kind in the UK and represents a significant revenue opportunity for Akers Bio,” said Akers chief executive John Gormally.

“Given Today's Group's customers' buying power, we are confident that sales of this product through Accutest will ramp up as they expand their marketing across an extensive network of UK wholesalers.”

Akers’ BreathScan alcohol detector is a single-use device that measures the user’s blood alcohol levels in just two minutes through a simple breath test.

Accutest is positioning device as a ‘morning after’ test where drivers can make sure they are safe to drive after consuming alcohol the night before.

View full AKR profile

Akers Biosciences, Inc. Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.